Clinical Trials Insight

全球临床试验追踪与评论平台

实时追踪全球顶级期刊最新临床试验

智能分析全球顶级期刊
临床试验成果

自动追踪 NEJM、Lancet、JAMA、BMJ 等顶级期刊最新发表的 I、II、III 期临床试验, 提供方法学漏洞分析与高质量 Correspondence 评论生成

421
已收录试验
17
顶级期刊
24h
自动更新

最新临床试验

按发表日期倒序排列 · 来源:NEJM、Lancet、JAMA、BMJ 等顶级期刊

Phase IILancet
Feb 28, 2026
Safety and efficacy of eslicarbazepine acetate for seizure prevention in patients with stroke at high risk of developing post-stroke epilepsy: a proof-of-concept, phase 2a, randomised, double-blind, placebo-controlled antiepileptogenesis trial.
The Lancet
适应症:Double-Blind Method; Dibenzazepines; Anticonvulsants
样本量:129 例

Eslicarbazepine acetate is an antiseizure medication that has shown potential antiepileptogenic effects in preclinical models of epilepsy. We aimed to investigate whether eslicarbazepine acetate could

查看分析 →全文
Phase IIILancet
Feb 28, 2026
Safety and efficacy of intensive task-specific training in people with recent spinal cord injury: a phase 3, pragmatic, randomised, assessor-blinded, superiority trial.
The Lancet
适应症:Spinal Cord Injuries; Resistance Training; Single-Blind Method
样本量:220 例

It is widely believed that intensive task-specific training enhances neurological recovery in people with spinal cord injury (SCI) by exploiting activity-dependent spinal plasticity. We aimed to deter

查看分析 →全文
Phase IIIDiabetes Care
Feb 28, 2026
Safety and Feasibility of a Fully Automated Insulin Delivery System: FCL@Home, a Multicenter Randomized Clinical Trial in Individuals With Type 1 Diabetes.
Diabetes Care
适应症:Diabetes Mellitus, Type 1; Adolescent; Insulin

Automated insulin delivery (AID) requiring manual premeal boluses are the standard of care for people with type 1 diabetes (T1D). We evaluated the safety and feasibility of the Automated Insulin Deliv

查看分析 →全文
Phase IIIDiabetes Care
Feb 28, 2026
The Effect of Midpregnancy Screening for Gestational Diabetes Mellitus on Pregnancy Outcomes: The TESGO Randomized Controlled Trial.
Diabetes Care
适应症:Pregnancy; Diabetes, Gestational; Pregnancy Outcome

Newborns delivered by women with gestational diabetes mellitus (GDM) have accelerated intrauterine growth earlier than the current recommended screening period. We aimed to determine whether universal

查看分析 →全文
Phase IIILancet
Feb 28, 2026
Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study.
The Lancet
适应症:Muscular Dystrophy, Duchenne; Double-Blind Method; Child
样本量:226 例

Gene transfer is a promising therapeutic approach for Duchenne muscular dystrophy as the disease results from mutations in a single gene. Fordadistrogene movaparvovec is an investigational recombinant

查看分析 →全文
Phase IIIJAMA
Feb 23, 2026
A Lay Health Worker-Led Symptom Intervention and Acute Care Use in Older Adults With Cancer: A Randomized Clinical Trial.
JAMA
适应症:Neoplasms; Emergency Service, Hospital; Community Health Workers

Undertreated cancer symptoms are common among older adults, yet effective early identification and intervention remain limited. To determine whether lay health worker-led symptom assessment reduces ac

查看分析 →全文
Phase IIIJAMA
Feb 23, 2026
Minor Papillotomy for Treatment of Idiopathic Acute Pancreatitis With Pancreas Divisum: A Randomized Clinical Trial.
JAMA
适应症:Cholangiopancreatography, Endoscopic Retrograde; Pancreatitis; Pancreas
样本量:148 例

Pancreas divisum is implicated as an obstructive cause for acute pancreatitis. Observational data suggest endoscopic retrograde cholangiopancreatography (ERCP) with minor papillotomy reduces the risk

查看分析 →全文
Phase IIIJAMA
Feb 23, 2026
Intraoperative Driving Pressure-Guided High PEEP vs Standard Low PEEP for Postoperative Pulmonary Complications.
JAMA
适应症:Positive-Pressure Respiration; Postoperative Complications; Lung Diseases

The effect of individualized high positive end-expiratory pressure (PEEP) and recruitment maneuvers, targeting a low driving pressure, on clinical outcomes in patients undergoing open abdominal surger

查看分析 →全文
Phase IIIEHJ
Feb 22, 2026
Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial.
European Heart Journal
适应症:Heart-Assist Devices; Aspirin; Double-Blind Method

Left ventricular assist devices (LVADs), including the HeartMate 3 (HM3), have improved outcomes in patients with advanced heart failure. Use of vitamin K antagonists (VKA) is mandated to reduce the r

查看分析 →全文
Phase IIILancet
Feb 20, 2026
Cumulative incidence of advanced breast cancer in women aged 40-49 years in the Japan Strategic Anti-cancer Randomised Trial (J-START) of adjunctive ultrasonography: a prespecified secondary analysis.
The Lancet
适应症:Breast Neoplasms; Incidence; Japan

The J-START randomised controlled trial found that adjunctive ultrasonography was associated with significantly higher rates of breast cancer detection than mammography alone. This report aims to eval

查看分析 →全文
Phase INEJM
Feb 18, 2026
An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.
New England Journal of Medicine
适应症:Myotonic Dystrophy; Double-Blind Method; Oligonucleotides

Myotonic dystrophy type 1 is a rare, dominantly inherited, progressive, disabling, neuromuscular disease that leads to decreased life expectancy and has no approved therapies. The disease is caused by

查看分析 →全文
Phase INEJM
Feb 18, 2026
Hematopoietic Stem-Cell Gene Therapy for Cystinosis.
New England Journal of Medicine
适应症:Cystinosis; Genetic Therapy; Hematopoietic Stem Cell Transplantation

Cystinosis is a multisystemic lysosomal storage disorder caused by pathogenic variants in CTNS, the gene encoding cystinosin, a lysosomal transmembrane cystine transporter. In patients with cystinosis

查看分析 →全文
Phase IIIBMJ
Feb 16, 2026
Vitamin D supplementation before in vitro fertilisation in women with polycystic ovary syndrome: multicentre, double blind, placebo controlled, randomised clinical trial.
BMJ
适应症:Polycystic Ovary Syndrome; Double-Blind Method; Fertilization in Vitro
样本量:876 例

To evaluate whether vitamin D supplementation improves live birth rates in women with polycystic ovary syndrome undergoing in vitro fertilisation. Multicentre, double blind, placebo controlled, random

查看分析 →全文
Phase IIIJAMA
Feb 16, 2026
Cryopreserved vs Liquid-Stored Platelets for the Treatment of Surgical Bleeding: The CLIP-II Randomized Noninferiority Clinical Trial.
JAMA
适应症:Platelet Transfusion; Cryopreservation; Double-Blind Method

Liquid-stored platelets have a shelf-life of 5 to 7 days, limiting availability and resulting in wastage. To assess the effectiveness and safety of dimethyl sulfoxide-cryopreserved platelets, which ha

查看分析 →全文
Phase IIIJAMA
Feb 16, 2026
Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants: The PDA Randomized Clinical Trial.
JAMA
适应症:Ductus Arteriosus, Patent; Infant, Newborn; Indomethacin

The management of patent ductus arteriosus (PDA) in preterm infants is controversial. To determine whether expectant management compared with active treatment of a protocol-defined PDA in preterm infa

查看分析 →全文
Phase IINat Med
Feb 15, 2026
A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial.
Nature Medicine
适应症:Major Depressive Disorder; Double-Blind Method; Hallucinogens
样本量:34 例

Major depressive disorder (MDD) is a leading cause of disability worldwide, yet many patients have inadequate responses to current treatments. Dimethyltryptamine (DMT), a serotonergic psychedelic with

查看分析 →全文
Phase INat Med
Feb 11, 2026
Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy.
Nature Medicine
适应症:HIV Infections; Programmed Cell Death 1 Receptor; HIV-1

Antiretroviral therapy (ART) suppresses HIV but does not eliminate the latent viral reservoir, which persists in programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. Anti-PD-1 therapies hav

查看分析 →全文
Phase IIIEHJ
Feb 10, 2026
Remote ischaemic conditioning improves outcomes of ischaemic stroke treated by endovascular thrombectomy: the SERIC-EVT trial.
European Heart Journal
适应症:Thrombectomy; Ischemic Stroke; Endovascular Procedures
样本量:498 例

Even after endovascular thrombectomy, more than half of patients with acute large vessel occlusion stroke do not achieve favourable outcomes. This study aimed to assess the efficacy and safety of remo

查看分析 →全文
Phase IIIEHJ
Feb 10, 2026
Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.
European Heart Journal
适应症:Heart Failure; Stroke Volume; Double-Blind Method

In the VICTOR trial (NCT05093933), vericiguat was neutral for the primary composite endpoint of cardiovascular death or hospitalization for heart failure (HF). VICTOR was powered to independently asse

查看分析 →全文
Phase IIIEHJ
Feb 10, 2026
Early antiplatelet treatment for minor stroke following thrombolysis: the EAST trial.
European Heart Journal
适应症:Platelet Aggregation Inhibitors; Double-Blind Method; Clopidogrel
样本量:1,022 例

Antiplatelet treatment is recommended to start 24 h after intravenous thrombolysis due to concerns about haemorrhagic transformation. This study aimed to investigate the potential benefit of ea

查看分析 →全文
Phase IIIEHJ
Feb 10, 2026
Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial.
European Heart Journal
适应症:Renal Artery Obstruction; Hypertension, Renovascular; Stents
样本量:101 例

The optimal therapy for patients with atherosclerotic renal artery stenosis (ARAS) remains unresolved. This study compared the efficacy of renal fractional flow reserve (FFR)-guided revascularization

查看分析 →全文
Phase IIIEHJ
Feb 10, 2026
Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial.
European Heart Journal
适应症:Aspirin; Acute Coronary Syndrome; Platelet Aggregation Inhibitors
样本量:2,484 例

Despite current antithrombotic treatments, the recurrence of ischaemic events remains high in patients with diabetes mellitus (DM) or aspirin resistance after acute coronary syndrome (ACS). Whether tw

查看分析 →全文
Phase IIIEHJ
Feb 10, 2026
Improving outcomes of atrial fibrillation ablation by integrated personalized lifestyle interventions: a randomized controlled trial.
European Heart Journal
适应症:Atrial Fibrillation; Catheter Ablation; Prospective Studies
样本量:70 例

Atrial fibrillation (AF) is associated with various lifestyle risk factors. Their presence negatively affects AF catheter ablation outcomes. This study evaluates the efficacy of a nurse-led, integrate

查看分析 →全文
Phase IIIEHJ
Feb 10, 2026
Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial.
European Heart Journal
适应症:Adrenergic beta-Antagonists; Sex Factors; Myocardial Infarction

Recent trials have challenged the guideline recommendation of beta-blockers for post-myocardial infarction (MI) patients without reduced left ventricular ejection fraction (LVEF). Whether these recent

查看分析 →全文
Phase IIIBMJ
Feb 9, 2026
Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.
BMJ
适应症:Nasopharyngeal Carcinoma; Antibodies, Monoclonal, Humanized; Nasopharyngeal Neoplasms
样本量:390 例

To assess treatment with camrelizumab (a programmed death 1 inhibitor) in addition to concurrent chemoradiotherapy and as a maintenance treatment in patients with high risk nasopharyngeal carcinoma. M

查看分析 →全文
Phase IIIJAMA
Feb 9, 2026
Spinal Manipulation and Clinician-Supported Biopsychosocial Self-Management for Acute Back Pain: The PACBACK Randomized Clinical Trial.
JAMA
适应症:Self-Management; Manipulation, Spinal; Low Back Pain

Low back pain (LBP) is influenced by interrelated physical, psychological, and social factors. However, most treatments focus on symptom reduction without addressing the underlying biopsychosocial nee

查看分析 →全文
Phase IIIJAMA
Feb 9, 2026
Targeted Oxygen for Initial Resuscitation of Preterm Infants: The TORPIDO 30/60 Randomized Clinical Trial.
JAMA
适应症:Infant, Newborn; Resuscitation; Infant, Premature

The most effective initial fraction of inspired oxygen (Fio2) for resuscitating preterm newborns is unknown. To compare outcomes of newborns born at 23 to 28 weeks' gestation resuscitated with initial

查看分析 →全文
Phase IIIJAMA
Feb 9, 2026
Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial.
JAMA
适应症:Valacyclovir; Alzheimer Disease; Antiviral Agents

Neuroscientific, epidemiological, and electronic health record studies implicate herpes simplex virus (HSV) as potentially etiological for Alzheimer disease (AD). To compare the efficacy and adverse e

查看分析 →全文
Phase IIIEHJ
Feb 8, 2026
Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial.
European Heart Journal
适应症:Tomography, Optical Coherence; Percutaneous Coronary Intervention; Coronary Artery Disease

This study evaluated the incidence, determinants, and clinical impact of stent optimization after optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI) for complex lesions

查看分析 →全文
Phase IIINat Med
Feb 8, 2026
Reliability of LLMs as medical assistants for the general public: a randomized preregistered study.
Nature Medicine
适应症:Language; Reproducibility of Results; Health Personnel

Global healthcare providers are exploring the use of large language models (LLMs) to provide medical advice to the public. LLMs now achieve nearly perfect scores on medical licensing exams, but this d

查看分析 →全文
顶级期刊已发表案例

同类 Correspondence 已在顶级期刊发表

以下为 NEJM、Lancet、JAMA、BMJ 已发表的真实 Correspondence / Letter 案例, 展示平台生成的评论与顶级期刊发表标准高度一致——相同的批评视角、相同的方法学深度。

NEJM2026
Correspondence
Beta-Blockers after Myocardial Infarction
针对:REBOOT Trial (N Engl J Med 2025)
Statistical Power

Statistical power concerns in REBOOT trial: despite reaching planned sample size, the confidence interval (HR 1.04; 95% CI 0.89–1.22) does not exclude a clinically meaningful harm or benefit, raising concerns about the robustness of the null conclusion.

DOI: 10.1056/NEJMc2518019查看原文
BMJ2025
Rapid Response
Lack of Blinding: A Critical Source of Performance Bias
针对:Frozen vs Fresh Embryo Transfer RCT (BMJ 2025)
Blinding / Performance Bias

Open-label design in IVF trial allowed clinicians to transfer significantly more double cleavage-stage embryos in the fresh arm (58.8% vs 49.6%), artificially inflating the live birth rate difference (40.1% vs 31.5%). Performance bias from unblinded allocation undermines causal inference.

DOI: 10.1136/bmj-2024-081474查看原文
NEJM2020
Correspondence
A Trial of Lopinavir–Ritonavir in Covid-19
针对:Lopinavir–Ritonavir COVID-19 Trial (N Engl J Med 2020)
Sample Size / Confounding

Underpowered single-centre trial with late treatment initiation (median 13 days post-onset). Concurrent uncontrolled glucocorticoid use (33% of patients) confounded viral load outcomes. Secondary outcomes suggested potential mortality benefit (19% vs 25%) that the trial was insufficiently powered to confirm.

DOI: 10.1056/NEJMc2008043查看原文
Lancet2024
Correspondence
Counting the dead in Gaza: difficult but essential
针对:Gaza conflict mortality data (Lancet 2024)
Ascertainment Bias / Underreporting

Methodological critique of passive surveillance data: official death counts underestimate true mortality by excluding indirect deaths from infrastructure collapse. Authors estimate true excess mortality may be 4× the reported figure, highlighting systematic undercounting bias in conflict-zone epidemiology.

DOI: 10.1016/S0140-6736(24)01169-3查看原文
JAMA2014
Letter
Allocation Concealment in Clinical Trials
针对:Systematic review of RCT allocation concealment (JAMA 2002–2014)
Allocation Concealment

High-scoring allocation concealment and double-blinding are independently associated with smaller treatment effect estimates (OR 0.87; 95% CI 0.79–0.96). Trials with inadequate concealment overestimate treatment effects by 13–41%, a systematic bias that inflates apparent efficacy across therapeutic areas.

DOI: 10.1001/jama.2013.285901查看原文
Lancet2025
Response Letter
Response to Letter by Dr. Verbeck — eClinicalMedicine
针对:Meta-analysis of 154 RCTs (eClinicalMedicine 2025)
Heterogeneity / Subgroup Analysis

Authors defend methodological rigour of a 154-RCT meta-analysis (112,515 participants) against critique of heterogeneity and subgroup validity. Exchange illustrates standard post-publication peer review process: challenging I² thresholds, subgroup pre-specification, and sensitivity analysis robustness.

DOI: 10.1016/S2589-5370(25)00611-X查看原文

平台生成的 Correspondence 与上述案例同等水准

选择一篇最新临床试验 → 一键生成方法学分析 → 直接投稿目标期刊

平台核心功能

智能提取

自动提取试验设计、统计指标(HR/CI/P值)、关键结果等结构化信息

漏洞识别

识别分配隐藏、盲法缺陷、统计功效不足等方法学漏洞,按风险等级分类

一键生成评论

自动生成500词结构化英文 Correspondence 评论,可直接投稿顶级期刊

订阅通知

按疾病领域、试验阶段、期刊自定义订阅,及时获取最新试验动态